Development of an inactivated vaccine candidate for SARS-CoV-2

Journal: Science

Published: 2020-07-03

DOI: 10.1126/science.abc1932

Affiliations: 10

Authors: 34

Go to article
Institutions Share
Sinovac Biotech Co., Ltd., China 0.44
Zhejiang Provincial Center for Disease Control and Prevention (Zhejiang CDC), China CDC, China 0.12
CAS Key Laboratory of Infection and Immunity, IBP CAS, China 0.07
National Laboratory of Biomacromolecules (NLB), IBP CAS, China 0.07
Division of Respiratory Virus Vaccines, NIFDC, China 0.06
National Institute for Communicable Disease Control and Prevention, China CDC, China 0.06
MOH Key Laboratory of Human Disease Comparative Medicine, CAMS & PUMC, China 0.05
Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, CAMS & PUMC, China 0.05
Comparative Medicine Center, CAMS & PUMC, China 0.05
Beijing Institute of Microbiology and Epidemiology, AMMS, China 0.03

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER